Inactive Instrument

Yumanity Therapeutics

Equities

YMTX

US98872L1026

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Kineta's Shares Gain Momentum on Nasdaq Debut Following Yumanity Therapeutics Reverse Merger Completion MT
Kineta, Yumanity Therapeutics Complete Reverse Merger MT
Yumanity Therapeutics Inc.(NasdaqCM:KA) dropped from NASDAQ Composite Index CI
Kineta, Inc. completed the acquisition of Yumanity Therapeutics, Inc. from a group of shareholders in a reverse merger transaction. CI
Sector Update: Health Care Stocks Stage Small Recovery Late MT
Sector Update: Health Care MT
Top Midday Decliners MT
Stocks Remain Relatively Flat as Investors Wait for Fed Rate-Hike Move MT
Investors Remain Sidelined in Premarket Trading Ahead of Fed Decision Wednesday MT
Top Premarket Decliners MT
Daehan Green Power Corporation agreed to acquire 5.58% stake in Yumanity Therapeutics, Inc. for KRW 1.3 billion. CI
Sector Update: Healthcare Stocks Slide Monday but Outperform Most Sectors MT
Sector Update: Health Care Stocks Pulled Lower by Sinking Biotechs MT
Yumanity Therapeutics to Pay Special Cash Dividend Related to Planned Asset Sale, Kineta Merger -- Shares Rise MT
Economic Data Outlook Prompts Weak Open for US Equities MT
Top Premarket Gainers MT
Yumanity Therapeutics Declares Special Dividend, Payable in Cash on or Before December 29, 2022 CI
Yumanity Therapeutics Inc. announced that it has received $7.500001 million in funding from Growth & Value Development Co., Ltd. CI
Yumanity Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Yumanity Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Earnings Flash (YMTX) YUMANITY THERAPEUTICS Reports Q2 Revenue $1.66M MT
Sector Update: Health Care Stocks Slip Amid Losses for Biotechs MT
Sector Update: Health Care Stocks Edging Higher This Afternoon MT
Sector Update: Health Care MT
US Stocks Weakening in Midday Trading but Largely Staying on Positive Ground MT
Chart Yumanity Therapeutics
More charts
Yumanity Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of disease-modifying therapies for neurodegenerative diseases. The Company's pipeline consists of programs focused on Parkinson's disease, Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease. The Company's technology platform enables the rapid screening for disease targets and disease modifying drugs that can overcome toxicity in disease-causing gene networks, which results from an aberrant accumulation of misfolded proteins in the brain. The Company's product candidate includes YTX-7739, which is in Phase I clinical trials for the treatment and disease modification of Parkinson's disease.
Sector
-
More about the company
  1. Stock
  2. Equities
  3. Stock Yumanity Therapeutics - Nasdaq
  4. News Yumanity Therapeutics
  5. Yumanity Therapeutics to Receive $5 Million Milestone Payment From Merck